The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Targeting CCR5 with leronlimab in colorectal cancer
Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, explores the potential of CCR5 inhibitors in treating metastatic colorectal cancer and other “”cold”” tumors. Originally developed for HIV treatment, these drugs may stimulate immune cells and transform the tumor microenvironment from immune-resistant to immune-responsive. Leronlimab, a weekly subcutaneous CCR5 inhibitor, has shown historical benefits in triple-negative breast cancer and microsatellite stable colorectal cancer. A new prospective clinical trial is combining leronlimab with trifluridine plus tipiracil and bevacizumab in metastatic colorectal cancer patients to evaluate effectiveness at different dose levels. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The CCR5 very interesting story of stimulating the immune cells in metastatic colorectal cancer and other types of cancer. These drugs were developed actually in for HIV which uses CCR5 to get into cells. So we think these have immunogenic properties and manipulate the tumor immune microenvironment to be a little bit more friendly and again turning sort of these cold tumors hot and using leronlimab which is a sub-q weekly medication they’ve seen now historically patients with triple negative breast cancer but other tumor types like cold tumors like colorectal cancer and microsatellite stable that seem to derive benefits so this is older historical data that we’re presenting but it’s informing the the development of a recently launched ongoing prospective clinical trial combining Leronlimab a CCR5 inhibitor and patients with colorectal cancer are also being treated with lonsurf and bevacizumab...
The CCR5 very interesting story of stimulating the immune cells in metastatic colorectal cancer and other types of cancer. These drugs were developed actually in for HIV which uses CCR5 to get into cells. So we think these have immunogenic properties and manipulate the tumor immune microenvironment to be a little bit more friendly and again turning sort of these cold tumors hot and using leronlimab which is a sub-q weekly medication they’ve seen now historically patients with triple negative breast cancer but other tumor types like cold tumors like colorectal cancer and microsatellite stable that seem to derive benefits so this is older historical data that we’re presenting but it’s informing the the development of a recently launched ongoing prospective clinical trial combining Leronlimab a CCR5 inhibitor and patients with colorectal cancer are also being treated with lonsurf and bevacizumab. So we’re excited that this study is up and running and hope to really establish, you know, how much loranlimab is contributing at two different dose levels.
Read more...
